Chemotherapy with or without tocilizumab for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and able to sign consent and privacy paperwork
- Have breast cancer that is triple-negative or ER-low (ER and PR are 9% or less on staining), and is metastatic or has returned locally but cannot be cured with surgery/radiation
- Have had no more than 2 prior treatment lines for metastatic disease
- Plan to receive standard-of-care chemotherapy (your oncologist chooses the chemo plan that fits guidelines)
- Have “measurable” tumor spots on scans and good general health (ECOG performance status 0–1)
- If you have brain metastases, they must be treated and stable for more than 4 weeks, and you may need a brain scan at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a new combination of drugs for triple negative breast cancer that has worsened after prior immunotherapy. The goal is to see if these treatments can shrink tumors and help patients who have not responded to earlier immunotherapies.
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.